The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).
GlobalData on MSN2d
Four regimens fail endpoints simultaneously in HEALEY ALS trialALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...
European Union trade chief Maros Sefcovic said on Thursday that his top priority in trade talks with President Donald Trump's ...
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
Originally scheduled for next week, the meeting of agency advisers will be delayed to give more time for public comment, according to an HHS spokesperson.
Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...
According to DelveInsight’s analysis, the epilepsy market is expected to grow due to an increase in disease prevalence and the expected launch of emerging therapies such as Xenon Pharmaceutical’s ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
New weight-loss treatments are being developed to preserve or increase muscle mass while shedding pounds. Companies like Eli Lilly, Regeneron, and Roche are focusing on therapies that target proteins ...
Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback